The Cell Therapy Catapult, which focuses on the development of the UK cell therapy industry, said it will work with London-based GlaxoSmithKline plc to explore potential collaborations in a range of areas relevant to the development of cell therapies, from research projects to technical and regulatory strategy
In addition to the stock investment, Aradigm may receive up to $25 million in development milestones, along with tiered royalties...Baxter said it will introduce HyQvia in select countries during 2013 and plans to expand the launch to other EU countries in 2014...Other data demonstrated that pharmacological inhibition of Usp14 by the company's small-molecule inhibitors stimulated degradation of the proteins in cell, neuron and brain slice models, suggesting the compounds' potential in a number of
The company plans to move ASM-024 into a Phase II trial in COPD later this year...His contributions to the field of oncology include more than 20 compounds brought into development, including the recently approved anticancer drugs Xalkori (crizotinib) and Inlyta (axitinib), discovered at Pfizer where O'Connor served as the global research therapeutic area head for oncology...Relmada is seeking to move LevoCap through approval using the 505(b)(2) pathway. (See BioWorld Today, Aug. 24, 2012
In addition to RA and Crohn's, the pharma may develop GLPG0634 in psoriasis, irritable bowel syndrome and lupus, mirroring the path by which the label on its blockbuster Humira (adalimumab) was expanded beyond RA. (See BioWorld Today, March 1, 2012, and Jan. 3, 2013...SciClone agreed to make additional payments of $10 million if Zensun receives approval of Neucardin by subcutaneous infusion, and further indications and improved product forms could result in additional payments...Prior to the
Fenofibrate Tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides and apolipoprotein B, and to increase high-density lipoprotein cholesterol in adult patients with primary hypercholesterolemia or mixed dyslipidemia
Evotec will work to specifically target peptidoglycan biosynthesis, and will be responsible for commercialization of assets resulting from the collaboration...to produce and supply 123I-labeled NAV5001 for Navidea's late-phase clinical trials...Compared to the placebo group, animals treated with WF10 showed a reduction of the degree of symptoms
Mission Bay Capital committed to fund up to $500,000 per company...The company plans to use proceeds to repurchase common stock and for general corporate purposes, including the repayment of outstanding commercial paper borrowings and upcoming debt maturities
Common stock in Fibrocell Science Inc., of Exton, Pa., has been approved for listing on the NYSE Market, to commence trading on May 17, under the ticker symbol FCSC...Genfit SA, of Lille, France, said GFT505 reduced a new component of cardiovascular risk, remnant cholesterol, contained in lipid particles other than LDL and HDL...In the GFT505-209-4 study, the effect of GFT505 on measured remnant cholesterol was -24 percent (p = 0.0046) compared to the placebo group after 28 days of treatment
GW Pharmaceuticals plc, of Porton Down, UK, received commercial approval for lead cannabinoid product Sativex in Italy for moderate to severe spasticity in multiple sclerosis patients who have not responded adequately to other anti-spasticity medications...In other news, closed its initial public offering (IPO) of 3.5 million American depository shares (ADSs) at $8.90 per share...PM01183 is designed to bind covalently to the minor groove of DNA to induce a specific degradation in tumor cells of RNA
Prior to the approval of Nymalize, nimodipine was available only in gel capsule form...The company expects to complete the trial in the first half of 2014. (See BioWorld Today, Dec. 20, 2012...distribution rights to the drug, a next-generation micellar diblock co-polymeric paclitaxel formulation, from Samyang
Janssen Research & Development LLC, of Raritan, N.J., a unit of Johnson & Johnson, said the FDA granted priority review to its new drug application for simeprevir (TMC435), an NS3/4A protease inhibitor for once-daily administration with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adults with compensated liver disease...Valeant Pharmaceuticals International Inc., of Laval, Quebec, has provided additional information related to the proposal to continue
Kinnovata plans to develop, manufacture and commercialize respiratory products for China and other regional Asian markets, initially exploiting Vectura's Clickhaler and Duohaler dry powder inhaler (DPI) technology platforms in asthma and chronic obstructive pulmonary disease...KingYork is expected to hold a 50 percent equity share, with Vectura holding 35 percent and Zendex and partners holding 15 percent
We note that an acquisition of Warner could potentially offer a tax strategy as Warner has a lower tax rate...Regeneron waived its right to opt in on canakinumab and, instead, is entitled to sales royalties
formed a joint venture to commercialize Vectibix (panitumumab) in China...The split is intended to increase the per-share trading price of the common stock to satisfy the $1 minimum bid price requirement for continued listing on the Nasdaq Capital Market
rights to market Pertzye (pancrelipase) for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis...The board is recommending that shareholders approve the arrangement resolution, which is intended, among other goals, to improve Mirati's ability to attract funding in the larger U.S
Merck expects the review for this BLA, as well as a BLA for its Timothy grass pollen (Phleum pretense) sublingual allergy immunotherapy tablet, to be completed in the first half of 2014
To date, 130 laboratory-confirmed cases of human infection with the H7N9 virus, resulting in 31 deaths, have been reported to the World Health Organization...To date the company is known for its biodegradable and low toxicity DNA and RNA delivery reagents for cell-based research and therapeutics
The Cell Therapy Catapult, which focuses on the development of the UK cell therapy industry, said it will work with London-based GlaxoSmithKline plc to explore potential collaborations in a range of areas relevant to the development of cell therapies, from research projects to technical and regulatory strategy